{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:48:20Z","timestamp":1764510500889},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,1,26]],"date-time":"2015-01-26T00:00:00Z","timestamp":1422230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,1,26]],"date-time":"2015-01-26T00:00:00Z","timestamp":1422230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1038\/bmt.2014.304","type":"journal-article","created":{"date-parts":[[2015,1,26]],"date-time":"2015-01-26T19:00:30Z","timestamp":1422298830000},"page":"499-504","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant"],"prefix":"10.1038","volume":"50","author":[{"given":"L","family":"Castagna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Crocchiolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Carlo-Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Sarina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Gandolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Todisco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Balzarotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Anastasia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Magagnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Brusamolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,1,26]]},"reference":[{"key":"BFbmt2014304_CR1","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065\u20132071.","journal-title":"Lancet"},{"key":"BFbmt2014304_CR2","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","volume":"336","author":"AM Gianni","year":"1997","unstructured":"Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290\u20131297.","journal-title":"N Engl J Med"},{"key":"BFbmt2014304_CR3","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"27","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 27: 4184\u20134190.","journal-title":"J Clin Oncol"},{"key":"BFbmt2014304_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2141.2005.05603.x","volume":"130","author":"KM Ardeshna","year":"2005","unstructured":"Ardeshna KM, Kakouros N, Qian W, Powell MG, Saini N, D'Sa S et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol 2005; 130: 363\u2013372.","journal-title":"Br J Haematol"},{"key":"BFbmt2014304_CR5","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","volume":"119","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012; 119: 1665\u20131670.","journal-title":"Blood"},{"key":"BFbmt2014304_CR6","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183\u20132189.","journal-title":"J Clin Oncol"},{"key":"BFbmt2014304_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3324\/haematol.2012.069393","volume":"98","author":"A Gibb","year":"2013","unstructured":"Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013; 98: 611\u2013614.","journal-title":"Haematologica"},{"key":"BFbmt2014304_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjh.12120","volume":"160","author":"G Corazzelli","year":"2013","unstructured":"Corazzelli G, Angrilli F, D'Arco A, Ferrara F, Musto P, Guarini A et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol 2013; 160: 207\u2013215.","journal-title":"Br J Haematol"},{"key":"BFbmt2014304_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/bjh.12821","volume":"166","author":"A Anastasia","year":"2014","unstructured":"Anastasia A, Carlo-Stella C, Corradini P, Salvi F, Rusconi C, Pulsoni A et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol 2014; 166: 140\u2013142.","journal-title":"Br J Haematol"},{"key":"BFbmt2014304_CR10","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM et al. Panobinostat in patients with relapsed\/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012; 30: 2197\u20132203.","journal-title":"J Clin Oncol."},{"key":"BFbmt2014304_CR11","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","volume":"115","author":"B Sarina","year":"2010","unstructured":"Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM et al. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood 2010; 115: 3671\u20133677.","journal-title":"Blood"},{"key":"BFbmt2014304_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/bmt.2012.116","volume":"48","author":"R Crocchiolo","year":"2013","unstructured":"Crocchiolo R, Castagna L, F\u00fcrst S, El-Cheikh J, Faucher C, Oudin C et al. Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2013; 48: 249\u2013252.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014304_CR13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/sj.bmt.1704492","volume":"33","author":"M Magagnoli","year":"2004","unstructured":"Magagnoli M, Castagna L, Bramanti S, Balzarotti M, Santoro A . Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen. Bone Marrow Transplant 2004; 33: 1067\u20131068.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2014304_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFbmt2014304_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 2007; 92: 35\u201341.","journal-title":"Haematologica"},{"key":"BFbmt2014304_CR16","first-page":"825","volume":"15","author":"D Przepiorka","year":"1994","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl 1994; 15: 825\u2013828.","journal-title":"Bone Marrow Transpl"},{"key":"BFbmt2014304_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/sj.bmt.1705490","volume":"38","author":"SZ Pavletic","year":"2006","unstructured":"Pavletic SZ, Lee SJ, Soci\u00e9 G, Vogelsang G . Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transpl 2006; 38: 645\u2013651.","journal-title":"Bone Marrow Transpl"},{"key":"BFbmt2014304_CR18","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/cncr.22911","volume":"110","author":"JE Filmont","year":"2007","unstructured":"Filmont JE, Gisselbrecht C, Cuenca X, Deville L, Ertault M, Brice P et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer 2007; 110: 1361\u20131369.","journal-title":"Cancer"},{"key":"BFbmt2014304_CR19","first-page":"490","volume":"91","author":"BW Schot","year":"2006","unstructured":"Schot BW, Pruim J, van Imhoff GW, Sluiter WJ, Vaalburg W, Vellenga E . The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica 2006; 91: 490\u2013495.","journal-title":"Haematologica"},{"key":"BFbmt2014304_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/10428190701885545","volume":"49","author":"R Crocchiolo","year":"2008","unstructured":"Crocchiolo R, Canevari C, Assanelli A, Lunghi F, Tassara M, Stanghellini ML et al. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation. Leuk Lymphoma 2008; 49: 727\u2013733.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt2014304_CR21","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","volume":"97","author":"R Devillier","year":"2012","unstructured":"Devillier R, Coso D, Castagna L, Brenot Rossi I, Anastasia A, Chiti A et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Haematologica 2012; 97: 1073\u20131079.","journal-title":"Haematologica"},{"key":"BFbmt2014304_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"A Sureda","year":"2012","unstructured":"Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study\u2014a prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97: 310\u2013317.","journal-title":"Haematologica"},{"key":"BFbmt2014304_CR23","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1002\/cncr.25357","volume":"116","author":"A Dodero","year":"2010","unstructured":"Dodero A, Crocchiolo R, Patriarca F, Miceli R, Castagna L, Ciceri F et al. Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. Cancer 2010; 116: 5001\u20135011.","journal-title":"Cancer"},{"key":"BFbmt2014304_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/ajh.20790","volume":"82","author":"L Castagna","year":"2007","unstructured":"Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory\/relapsed Hodgkin's lymphoma: a monocenter prospective study. Am J Hematol 2007; 82: 122\u2013127.","journal-title":"Am J Hematol"},{"key":"BFbmt2014304_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1365-2141.2012.09096.x","volume":"157","author":"S Moore","year":"2012","unstructured":"Moore S, Kayani I, Peggs K, Qian W, Lowry L, Thomson K et al. Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. Br J Haematol. 2012; 157: 543\u2013552.","journal-title":"Br J Haematol."},{"key":"BFbmt2014304_CR26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.bbmt.2011.11.028","volume":"18","author":"S Cohen","year":"2012","unstructured":"Cohen S, Kiss T, Lachance S, Roy DC, Sauvageau G, Busque L et al. Tandem autologous\u2013allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant 2012; 18: 951\u2013957.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014304_CR27","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.1200\/JCO.2007.15.5887","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"Morschhauser F, Brice P, Ferm\u00e9 C, Divin\u00e9 M, Salles G, Bouabdallah R et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse\/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA\/SFGM study group. J Clin Oncol 2008; 26: 5980\u20135987.","journal-title":"J Clin Oncol"},{"key":"BFbmt2014304_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bbmt.2007.01.072","volume":"13","author":"HC Fung","year":"2007","unstructured":"Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant 2007; 13: 594\u2013600.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014304_CR29","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1200\/JCO.2004.07.131","volume":"22","author":"SM Devine","year":"2004","unstructured":"Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095\u20131102.","journal-title":"J Clin Oncol"},{"key":"BFbmt2014304_CR30","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641\u2013650.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2014304_CR31","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","volume":"31","author":"AJ Moskowitz","year":"2013","unstructured":"Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013; 31: 456\u2013460.","journal-title":"J Clin Oncol"},{"key":"BFbmt2014304_CR32","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3324\/haematol.2012.083048","volume":"98","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F et al. Brentuximab vedotin in relapsed\/refractory Hodgkin\u2019s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 2013; 98: 1232\u20131236.","journal-title":"Haematologica"},{"key":"BFbmt2014304_CR33","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1182\/blood-2012-05-430918","volume":"120","author":"A Rothe","year":"2012","unstructured":"Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, J\u00e4ger U et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012; 120: 1470\u20131472.","journal-title":"Blood"},{"key":"BFbmt2014304_CR34","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1182\/blood-2012-03-418673","volume":"119","author":"R Chen","year":"2012","unstructured":"Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012; 119: 6379\u20136381.","journal-title":"Blood"},{"key":"BFbmt2014304_CR35","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.bbmt.2014.06.037","volume":"20","author":"R Chen","year":"2014","unstructured":"Chen R, Palmer JM, Tsai NC, Thomas SH, Siddiqi T, Popplewell L et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant 2014; 20: 1864\u20131868.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2014304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014304","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2014304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T18:07:16Z","timestamp":1648058836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2014304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,26]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["BFbmt2014304"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2014.304","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,26]]},"assertion":[{"value":"13 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}